Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Cancers · 29.06.2026 · 18 (13) · 2110
DOI: 10.3390/cancers18132110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.06.2026. Verfasst von Simona Andrea Ruckstuhl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Brexu-cel is an established CD19-directed CAR-T cell therapy for relapsed or refractory mantle cell lymphoma, but clinical outcomes are heterogeneous, and germline determinants of response are poorly defined.
Methods
We investigated the clinical impact of the CD19 single-nucleotide polymorphism rs2904880 on treatment outcome after brexu-cel CAR-T cell therapy by analyzing genotype-outcome associations in a retrospective single-center cohort of patients with relapsed or refractory mantle cell lymphoma treated with this CAR-T cell therapy.
Results
Overall survival varied according to CD19 polymorphism, with improved survival of patients carrying the V174 homozygous genotype compared with L174V heterozygotes.
Conclusions
The germline CD19 polymorphism may have implications for future risk stratification after brexu-cel CAR-T cell therapy in mantle cell lymphoma, but requires validation in larger, multicenter cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
- Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
- Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
ORCID-Profile: Katja Seipel, Martina Bertschinger, Ulrike Bacher, Thomas Pabst
Zitieren
APA
Ruckstuhl, S. A., Seipel, K., Shaforostova, I., Bertschinger, M., Bacher, U., & Pabst, T. (2026). Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma. Cancers, 18(13), 2110. https://doi.org/10.3390/cancers18132110
Vancouver
Ruckstuhl SA, Seipel K, Shaforostova I, Bertschinger M, Bacher U, Pabst T. Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma. Cancers. 2026;18(13):2110. doi:10.3390/cancers18132110
BibTeX
@article{Ruckstuhl2026,
author = {Ruckstuhl, Simona Andrea and Seipel, Katja and Shaforostova, Inna and Bertschinger, Martina and Bacher, Ulrike and Pabst, Thomas},
title = {Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2110},
doi = {10.3390/cancers18132110}
}
EUVIMED